Xagena.net - Update in Medicine

IMpower131 trial: Atezolizumab plus chemotherapy reduces the risk of disease worsening or death in the initial treatment of people with advanced squamous non-small cell lung cancer

IMpower131 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Atezolizumab ( Tecentriq ) plus chemotherapy ( Carboplatin and Abraxane [ albumin-bou ... read article

Phase 1 trial evaluating MVT-5873 in combination with first-line chemotherapy in pancreatic cancer: promising early results

Interim results from the ongoing phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in patients newly diagnosed with pancreatic and other CA19-9 positive malignancies ... read article

IMpower150 study: Atezolizumab and Bevacizumab plus chemotherapy reduce the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer

The phase III IMpower150 study met its co-primary endpoint of progression-free survival ( PFS ) and demonstrated that the combination of Atezolizumab ( Tecentriq ) and Bevacizumab ( Avastin ) plus c ... read article

Atezolizumab in people with previously treated advanced bladder cancer: IMvigor211 study did not meet its primary endpoint of overall survival compared to chemotherapy

The phase III IMvigor211 study, that evaluated Atezolizumab ( Tecentriq ) in people with locally advanced or metastatic urothelial cancer ( mUC ) whose disease progressed during or after treatment wit ... read article

Abraxane for metastatic pancreatic cancer, FDA approved

The Food and Drug Administration ( FDA ) has expanded the approved uses of Abraxane ( Paclitaxel protein-bound particles for injectable suspension, albumin-bound ) to treat patients with metastatic pa ... read article

Patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 drugs

New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset of patients wit ... read article

TRINOVA-1 trial: Trebananib in recurrent ovarian cancer study meets primary endpoint of progression-free survival

Amgen has announced that the Phase 3 TRINOVA-1 trial evaluating Trebananib plus Paclitaxel versus placebo plus Paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survi ... read article

Newly diagnosed ovarian cancer: Bevacizumab reduces the risk of disease progression during the first year of treatment

Adding Bevacizumab ( Avastin ) to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. The ICON7 trial included ... read article

Gefitinib does not improve overall survival in patients with advanced NSCLC with EGFR activating mutations

Data from the IPASS study showed that overall survival ( OS ) was similar, with no significant difference, between Gefitinib ( Iressa ) and Carboplatin / Paclitaxel ( doublet chemotherapy ) in the ove ... read article

Metastatic HER2+ breast cancer: triple drug combination is promising option

Combining two chemotherapy drugs with Trastuzumab ( Herceptin ) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. Researchers at ... read article

Breast cancer survival improves using Herceptin with chemotherapy

Using Herceptin ( Trastuzumab ) with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care. Patients using Herceptin ... read article

Metastatic HER2+ breast cancer: a combination of Capecitabine, Vinorelbine, and Trastuzumab is promising option

Combining two chemotherapy drugs with Trastuzumab ( Herceptin ) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th An ... read article

SPIRIT IV: Xience V has shown enhanced safety and efficacy in the treatment of de novo native coronary artery lesions compared to Taxus

Data from SPIRIT IV clinical trial, a large-scale multi-center study of nearly 4,000 patients in the United States, showed that Everolimus-eluting stents ( Xience V ) demonstrated enhanced safety and ... read article

Breast cancer: management and prognosis

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.The following abstracts have been presented at the CTRC-AACR ... read article